China Medical University

Chun-ching Shih

Hui-Ya Ho

Jin-Bin Wu

Wen-Chuan Lin

Hung-Bo Hsiao

Cheng-Hsiu Lin

Chun-Ching Shih

Chang-Chi Hsieh

Sze-Ying Chen

Hsin-Sheng Tsay

Wei-Lii Lin

Jia-Ying Jian

The present invention provides a method of treating or preventing type 2 diabetes and hyperlipidemia in a subject in need thereof, comprising administrating to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a pharmaceutical composition for treatment or prevention of type 2 diabetes and hyperlipidemia, comprising a compound of formula I and a pharmaceutically acceptable carrier. Through down-regulation of PEPCK, G6Pase, 11&#x3b2;-HSD1, DGAT2, and GPAT, up-regulation of PPAR&#x3b1; and adiponectin, and promotion of membrane GLUT4 expression and phosphorylation of AMPK and Akt, the compound of formula I of the present invention exerts antidiabetic and antihyperlipidemic effects, including reduced weight of visceral fat, decreased blood levels of triglycerides, free fatty acids, glucose, insulin, and leptin as well as decreased hepatic levels of total lipid and triacylglycerol. The compound of formula I also inhibits adipocyte hypertrophy and hepatic ballooning.

Method and composition for treatment or prevention of type 2 diabetes and hyperlipidemia

A pharmaceutical composition useful for hepatoprotection is provided. The composition comprises an effective amount of kinsenoside or a pharmaceutically acceptable salt or ester thereof. An aqueous extract ofspp. is also provided. The extract is substantially free of ethyl acetate-philic components.

[object Object]

A method for inhibiting the activity of matrix metalloproteinase (MMP), inhibiting the expression of matrix metalloproteinase, inhibiting the phosphorylation of mitogen-activated protein kinase (MAPK), and/or promoting the expression of collagen in a mammal is provided. The method comprises administrating to the mammal an effective amount of an active component selected from a group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound, and combinations thereof: 

Method for inhibiting activity and/or expression of matrix metalloproteinase, inhibiting phosphorylation of mitogen-activated protein kinase, and/or promoting expression of collagen using tormentic acid

Provided is a method for inhibiting the activation of macrophages in a subject, comprising administrating to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable ester of the compound, and combinations thereof: 

Method for inhibiting activation of macrophages

A method for inhibiting the activation of macrophages, inhibiting the formation of osteoclasts, inhibiting the function of osteoclasts, and/or activating osteoblasts in a mammal is provided. The method comprises the administration of an effective amount of kinsenoside of formula (I) or a pharmaceutically acceptable salt or ester thereof to the mammal: 

Method for inhibiting activation of macrophages, inhibiting formation of osteoclasts, inhibiting function of osteoclasts, and/or activating osteoblasts

Growing community of inventors

Taichung, Taiwan

Hui-Ya Ho